Bioheart Extends Licenses of Electrical Stimulation Patents With Airspeed
* Reuters is not responsible for the content in this press release.
SUNRISE, FL, Oct 17 (Marketwire) -- Bioheart, Inc. (OTCQB: BHRT) today announced that they have agreed to extend the license agreement with Airspeed for four separate Bioheart patents. The patents include methods of electrical stimulation and biological pacing, which are marketed under the MyoStim(TM) product line. Airspeed holds exclusive rights to these patents and all products associated with the patents and pays Bioheart milestone payments and royalties based on future sales of products. MyoStim is pursuing initial safety and efficacy trials in both wound care and heart failure using the Wound Healing and Regeneration Accelerator units (MWHA-1). Mike Tomas, President and CEO, said, "Bioheart is currently focused on our core assets for heart failure patients and is enthusiastic about Airspeeds ability to bring Bioheart's electrical stimulation technologies to market." Alan Remen, Airspeed Holdings' Managing Director and MyoStim's Co-Founder and CEO, said, "This technology may help to stimulate the body's own bio-electric 'homing' signal to recruit stem cells to the site of injury and grow new blood vessels, which can be an effective therapy for critical wounds and heart failure." About Bioheart, Inc. Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc. About Airspeed Holdings, LLC Headquartered in San Diego, Airspeed is a private investment, entrepreneurial capital management firm and leading edge, multi-project business development enterprise that creates and nurtures new technology companies. Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2012. Media Contact: Rhonda Madaris 13794 NW4th Street Suite 212 Sunrise, FL 33325 Telephone 954/835-1500 Email: firstname.lastname@example.org Copyright 2012, Marketwire, All rights reserved. -0-
- Atheists face death in 13 countries, global discrimination: study
- Missouri executes man for killing good Samaritan motorist in 1994
- Focus turns to Thai military, anti-government protesters tell them to pick sides
- Google executives' planes saved millions in costs due to error - NASA
- Apple scores legal victory over Samsung in South Korea